Citations

Showing 10 of 108036 citations.

Considering endpoints for comparative tolerability of cancer treatments using patient report given the estimand framework
Peipert, John Devin , Basch, Ethan , Cella, David , Smith, Mary Lou , Thanarajasingam, Gita , Peipert, John Devin , Breslin, Monique C. , Basch, Ethan , Calvert, Melanie , Roydhouse, Jessica

Mayo Clinic

Journal of Biopharmaceutical Statistics | February 15, 2024 | Volume: 35 | Issue: 5 | Pages: 793-811

10.1080/10543406.2024.2313060 | PMID 38358291 Get It

Unraveling the Genetic Landscape of Neurological Disorders: Insights into Pathogenesis, Techniques for Variant Identification, and Therapeutic Approaches
Firdaus, Zeba , Li, Xiaogang

Mayo Clinic

International Journal of Molecular Sciences | February 15, 2024 | Volume: 25 | Issue: 4 | Pages: 2320

10.3390/ijms25042320 | PMID 38396996 Get It

Genetic abnormalities play a crucial role in the development of neurodegenerative disorders (NDDs). Genetic exploration has indeed contributed to unraveling the molecular complexities responsible for the etiology and progression of various NDDs. The intricate nature of rare and common variants in NDDs contributes to a limited understanding of the genetic risk factors associated with them. Advancements in next-generation sequencing have made whole-genome sequencing and whole-exome sequencing possible, allowing the identification of rare variants with substantial effects, and improving the understanding of both Mendelian and complex neurological conditions. The resurgence of gene therapy holds the promise of targeting the etiology of diseases and ensuring a sustained correction. This approach is particularly enticing for neurodegenerative diseases, where traditional pharmacological methods have fallen short. In the context of our exploration of the genetic epidemiology of the three most prevalent NDDs—amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease, our primary goal is to underscore the progress made in the development of next-generation sequencing. This progress aims to enhance our understanding of the disease mechanisms and explore gene-based therapies for NDDs. Throughout this review, we focus on genetic variations, methodologies for their identification, the associated pathophysiology, and the promising potential of gene therapy. Ultimately, our objective is to provide a comprehensive and forward-looking perspective on the emerging research arena of NDDs.
Transforming Outcomes of Spine Surgery—Exploring the Power of Enhanced Recovery After Surgery Protocol: A Systematic Review and Meta-Analyses of 15 198 Patients
Magableh, Hamzah M , Ibrahim, Sufyan , Pennington, Zach , Nathani, Karim Rizwan , Johnson, Sarah E. , Freedman, Brett A. , Bydon, Mohamad , Pennington, Zachary, Katsos, Konstantinos, Pennington, Zach , Nathani, Karim Rizwan , Ibrahim, Sufyan , Katsos, Konstantinos

Mayo Clinic

Neurosurgery | February 15, 2024 | Volume: 95 | Issue: 1 | Pages: 3-25

10.1227/neu.0000000000002865 | PMID 38358272 Get It

BACKGROUND AND OBJECTIVES: Enhanced recovery after surgery (ERAS) protocols aim to optimize patient outcomes by reducing the surgical stress response, expediting recovery, and reducing care costs. We aimed to evaluate the impact of implementing ERAS protocols on the perioperative surgical outcomes and financial implications associated with spine surgeries. METHODS: A systematic review and meta-analysis of peer-reviewed studies directly comparing outcome differences between spine surgeries performed with and without utilization of ERAS pathways was conducted along Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: Of 676 unique articles identified, 59 with 15 198 aggregate patients (7748 ERAS; 7450 non-ERAS) were included. ERAS-treated patients had shorter operative times (mean difference [MD]: 10.2 mins; P < .01), shorter hospitalizations (MD: 1.41 days, P < .01), fewer perioperative complications (relative risk [RR] = 0.64, P < .01), lower postoperative opioid use (MD of morphine equivalent dose: 164.36 mg; P < .01), and more rapid mobilization/time to first out-of-bed ambulation (MD: 0.92 days; P < .01). Spine surgeries employing ERAS were also associated with lower total costs (MD: $1140.26/patient; P < .01), especially in the United States (MD: $2869.11/patient, P < .01) and lower postoperative visual analog pain scores (MD = 0.56, P < .01), without any change in odds of 30-day readmission (RR: 0.80, P = .13) or reoperation (RR: 0.88, P = .60). Subanalyses based on the region of spine showed significantly lower length of stay in both cervical and lumbar surgeries implementing ERAS. Type of procedure showed a significantly lesser time-to-initiate mobilization in fusion surgeries using ERAS protocols compared with decompression. CONCLUSION: The present meta-analysis indicates that current literature supports ERAS implementation as a means of reducing care costs and safely accelerating hospital discharge for patients undergoing spine surgery.
Vascular Diseases in Women: Do Women Suffer from Them Differently?
Farkas, Katalin , Stanek, Agata , Zbinden, Stéphanie, Borea, Barbara, Ciurica, Simina, Moore, Vanessa , Maguire, Peggy, Alajar, Elaine, Marcoccia, Antonella , Erer, Dilek , Casanegra, Ana I. , Sharebiani, Hiva , Sprynger, Muriel , Kavousi, Maryam , Catalano, M. , Casanegra, Ana I , Sharebiani, Hiva , Sprynger, Muriel , Kavousi, Maryam , Catalano, Mariella , Farkas, Katalin , Stanek, Agata , Ciurică, Simina , Moore, Vanessa, Abola, Maria Teresa B.

Mayo Clinic

Journal of Clinical Medicine | February 15, 2024 | Volume: 13 | Issue: 4 | Pages: 1108

10.3390/jcm13041108 | PMID 38398419 Get It

According to the World Health Organization, cardiovascular disease (CVD) is the leading cause of death among women worldwide, yet its magnitude is often underestimated. Biological and gender differences affect health, diagnosis, and healthcare in numerous ways. The lack of sex and gender awareness in health research and healthcare is an ongoing issue that affects not only research but also treatment and outcomes. The importance of recognizing the impacts of both sex and gender on health and of knowing the differences between the two in healthcare is beginning to gain ground. There is more appreciation of the roles that biological differences (sex) and sociocultural power structures (gender) have, and both sex and gender affect health behavior, the development of diseases, their diagnosis, management, and the long-term effects of an illness. An important issue is the knowledge and awareness of women about vascular diseases. The risk of cardiovascular events is drastically underestimated by women themselves, as well as by those around them. The purpose of this review is to draw attention to improving the medical care and treatment of women with vascular diseases.
What can we learn about skin of color in dermatopathology?
Wondimu, Bitania , Sokumbi, Olayemi , Sokumbi, Olayemi

Mayo Clinic

International Journal of Dermatology | February 15, 2024 | Volume: 63 | Issue: 5 | Pages: 557-559

10.1111/ijd.17048 | PMID 38357960 Get It

Abstract As the US population becomes increasingly diverse, more patients of color seek dermatologic care and often have concerns that are unique to their skin color. Therefore, it is critically important that the knowledge gap in skin of color dermatology be urgently addressed. In addition to addressing the clinical gap in recognizing dermatologic disease in patients of color, the role of dermatopathology in bridging this gap remains unaddressed. Given the impact that skin color can have on the presentation and subsequent management of dermatologic diseases, understanding the current knowledge of the unique structural and histologic characteristics in skin of color may help give us insight on the role skin color should play in histopathologic diagnosis. In this paper, we bring insights into the role dermatopathology plays in addressing our knowledge of cutaneous disease in patients with skin of color. After we highlight issues to consider, we can begin to identify gaps in knowledge that still exist within dermatopathology that need to be addressed to ensure patients of all backgrounds receive equitable dermatologic care.
Humoral immune response and safety of SARS‐CoV‐2 vaccination in very early onset inflammatory bowel disease
Kastl, Arthur , Weaver, Kimberly N. , Zhang, Xian , Strople, Jennifer A., Adler, Jeremy, Kelsen, Judith R. , Dubinsky, Marla C. , Bousvaros, Athos, Watkins, Runa , Dai, Colin, Cross, Raymond, Higgins, Peter , Bewtra, Meenakshi , Bellaguarda, Emanuelle, Chun, Kelly , Zikry, Michael, Bastidas, Monique , Boccieri, Margie E., Firestine, Ann M. , Long, Millie D. , Adler, Jeremy, Ungaro, Ryan C. , Farraye, Francis A. , Boccieri, Margie , Kappelman, Michael D. , Adler, J

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | February 15, 2024 | Volume: 78 | Issue: 4 | Pages: 871-877

10.1002/jpn3.12142 | PMID 38356293 Get It

AbstractChildren with very early onset inflammatory bowel disease (VEO‐IBD) may respond differently to coronavirus disease 2019 (COVID‐19) immunization compared to healthy children or other patients with IBD. We recruited children with VEO‐IBD <6 years of age and younger following receipt of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine. Demographics, IBD characteristics, medication use, adverse events (AEs) and IBD exacerbations were collected. Blood draws (optional) were obtained for measurement of antireceptor binding domain (RBD) IgG antibodies following vaccination. Of 41 participants, none required emergency department visit or hospitalization due to AE, and only one experienced IBD exacerbation. Detectable antibody was present in 19/19 participants who provided blood sample; 6/7 participants (86%) had durable humoral response 12 months postvaccination. Children with VEO‐IBD experience robust humoral immune response to COVID‐19 immunization. Severe AEs were rare. These findings provide reassurance that children with VEO‐IBD respond well and safely to SARS‐CoV‐2 vaccination.
Association of Blood Metabolomics Biomarkers with Brain Metabolites and Patient-Reported Outcomes as a New Approach in Individualized Diagnosis of Schizophrenia
Krzyściak, Wirginia , Bystrowska, Beata , Karcz, Paulina , Chrzan, Robert , Bryll, Amira, Turek, Aleksander , Mazur, Paulina , Śmierciak, Natalia , Szwajca, Marta , Donicz, Paulina , Furman, Katarzyna, Pilato, Fabio , Kozicz, Tamás , Pilecki, Maciej , Kozicz, Tamas , Popiela, Tadeusz

Mayo Clinic

International Journal of Molecular Sciences | February 15, 2024 | Volume: 25 | Issue: 4 | Pages: 2294

10.3390/ijms25042294 | PMID 38396971 Get It

Given its polygenic nature, there is a need for a personalized approach to schizophrenia. The aim of the study was to select laboratory biomarkers from blood, brain imaging, and clinical assessment, with an emphasis on patients’ self-report questionnaires. Metabolomics studies of serum samples from 51 patients and 45 healthy volunteers, based on the liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS/MS), led to the identification of 3 biochemical indicators (cortisol, glutamate, lactate) of schizophrenia. These metabolites were sequentially correlated with laboratory tests results, imaging results, and clinical assessment outcomes, including patient self-report outcomes. The hierarchical cluster analysis on the principal components (HCPC) was performed to identify the most homogeneous clinical groups. Significant correlations were noted between blood lactates and 11 clinical and 10 neuroimaging parameters. The increase in lactate and cortisol were significantly associated with a decrease in immunological parameters, especially with the level of reactive lymphocytes. The strongest correlations with the level of blood lactate and cortisol were demonstrated by brain glutamate, N-acetylaspartate and the concentrations of glutamate and glutamine, creatine and phosphocreatine in the prefrontal cortex. Metabolomics studies and the search for associations with brain parameters and self-reported outcomes may provide new diagnostic evidence to specific schizophrenia phenotypes.
Cutaneous Malignant Mixed Tumor With Pulmonary Metastasis: A Case Report and Literature Review
Haberecht, Hannah B. , Warren, Krista, Guo, Ruifeng , Haberecht, Hannah, Guo, Ruifeng , Tekin, Burak

Mayo Clinic

The American Journal of Dermatopathology | February 14, 2024 | Volume: 46 | Issue: 4 | Pages: 212-217

10.1097/dad.0000000000002629 | PMID 38354373 Get It

Background: Cutaneous malignant mixed tumor (MMT) is a rare sweat gland–derived tumor characterized by admixed malignant epithelial cells and chondromyxoid stroma. Approximately 50 cases have been described in the literature. Metastasis, which may occur in more than one-third of cases, is most common in the lung. Methods: We summarized the clinicopathologic features of a patient with cutaneous MMT metastatic to the lungs. A literature review of similar cases was completed using Web of Science, Scopus, and PubMed databases. Results: A woman in her 70s presented with an enlarging mass on her left eyebrow; histopathologic examination showed large islands of atypical cells with increased mitotic activity, admixed with necrosis on a background of fibrotic and chondromyxoid stroma. Multiple lung nodules were identified during follow-up. Examination of a pulmonary core needle biopsy specimen was consistent with metastatic cutaneous MMT. Literature review identified 10 cases published between 1980 and 2017. Most primary tumors were large (≥4 cm). Local recurrence was uncommon, and the lung was the only metastatic site in 5 cases. Histopathologically, metastatic tumors were described as more cellular, with diminished stromal tissue compared with the primary lesion. Conclusion: This is 1 of the 11 reports of cutaneous MMT with metastasis to the lungs found in the English-language literature published after 1980. Of note, most reports were published before 1990, making this case study one of the few contemporary descriptions of cutaneous MMT with pulmonary metastases. We think that the present case report will increase the awareness of this rare tumor.
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization
Chen, Jiajia , Laverty, Daniel J. , Bale, Ashwin , Carlson, Brett L. , Porath, Kendra A. , Bakken, Katrina K. , Burgenske, Danielle M. , Decker, Paul A. , Vaubel, Rachael A. , Eckel‐Passow, Jeanette E. , Elmquist, William F. , Bale, Ashwin , Carlson, Brett L , Porath, Kendra A , Bakken, Katrina K , Burgenske, Danielle M , Decker, Paul A. , Vaubel, Rachael A , Eckel-Passow, Jeanette E , Bhargava, Rohit , Lou, Zhenkun , Harley, Brendan A C , Nagel, Zachary D , Gupta, Shiv K , Sarkaria, Jann N , Laverty, Daniel J , Talele, Surabhi , Bhargava, Rohit , Lou, Zhenkun , Hamerlik, Petra , Harley, Brendan A.C. , Gupta, Shiv K. , Sarkaria, Jann N.

Mayo Clinic

Science Translational Medicine | February 14, 2024 | Volume: 16 | Issue: 734 | Pages: No page available

10.1126/scitranslmed.adj5962 | PMID 38354228 Get It

ATM is a key mediator of radiation response, and pharmacological inhibition of ATM is a rational strategy to radiosensitize tumors. AZD1390 is a brain-penetrant ATM inhibitor and a potent radiosensitizer. This study evaluated the spectrum of radiosensitizing effects and the impact of TP53 mutation status in a panel of IDH1 wild-type (WT) glioblastoma (GBM) patient-derived xenografts (PDXs). AZD1390 suppressed radiation-induced ATM signaling, abrogated G 0 -G 1 arrest, and promoted a proapoptotic response specifically in p53-mutant GBM in vitro. In a preclinical trial using 10 orthotopic GBM models, AZD1390/RT afforded benefit in a cohort of TP53 -mutant tumors but not in TP53 -WT PDXs. In mechanistic studies, increased endogenous DNA damage and constitutive ATM signaling were observed in TP53 -mutant, but not in TP53 -WT, PDXs. In plasmid-based reporter assays, GBM43 ( TP53 -mutant) showed elevated DNA repair capacity compared with that in GBM14 (p53-WT), whereas treatment with AZD1390 specifically suppressed homologous recombination (HR) efficiency, in part, by stalling RAD51 unloading. Furthermore, overexpression of a dominant-negative TP53 (p53DD) construct resulted in enhanced basal ATM signaling, HR activity, and AZD1390-mediated radiosensitization in GBM14. Analyzing RNA-seq data from TCGA showed up-regulation of HR pathway genes in TP53 -mutant human GBM. Together, our results imply that increased basal ATM signaling and enhanced dependence on HR represent a unique susceptibility of TP53 -mutant cells to ATM inhibitor–mediated radiosensitization.
Academic Surgery in the Era of Large Language Models
Rengers, Timothy A. , Salehinejad, Hojjat , Thiels, Cornelius A.

Mayo Clinic

JAMA Surgery | February 14, 2024 | Volume: 159 | Issue: 4 | Pages: 445

10.1001/jamasurg.2023.6496 | PMID 38353991 Get It

ImportanceThis review aims to assess the benefits and risks of implementing large language model (LLM) solutions in an academic surgical setting.ObservationsThe integration of LLMs and artificial intelligence (AI) into surgical practice has generated international attention with the emergence of OpenAI’s ChatGPT and Google’s Bard. From an administrative standpoint, LLMs have the potential to revolutionize academic practices by reducing administrative burdens and improving efficiency. LLMs have the potential to facilitate surgical research by increasing writing efficiency, building predictive models, and aiding in large dataset analysis. From a clinical standpoint, LLMs can enhance efficiency by triaging patient concerns and generating automated responses. However, challenges exist, such as the need for improved LLM generalization performance, validating content, and addressing ethical concerns. In addition, patient privacy, potential bias in training, and legal responsibility are important considerations that require attention. Research and precautionary measures are necessary to ensure safe and unbiased use of LLMs in surgery.Conclusions and RelevanceAlthough limitations exist, LLMs hold promise for enhancing surgical efficiency while still prioritizing patient care. The authors recommend that the academic surgical community further investigate the potential applications of LLMs while being cautious about potential harms.